Advertisement
UK markets close in 2 hours 13 minutes

  • FTSE 100

    8,037.40
    +13.53 (+0.17%)
     

  • FTSE 250

    19,699.15
    +99.76 (+0.51%)
     

  • AIM

    753.12
    +3.94 (+0.53%)
     

  • GBP/EUR

    1.1610
    +0.0021 (+0.18%)
     

  • GBP/USD

    1.2386
    +0.0036 (+0.29%)
     

  • Bitcoin GBP

    53,398.13
    -17.41 (-0.03%)
     

  • CMC Crypto 200

    1,422.80
    +8.04 (+0.57%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    81.34
    -0.56 (-0.68%)
     

  • GOLD FUTURES

    2,325.60
    -20.80 (-0.89%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,061.09
    +200.29 (+1.12%)
     

  • CAC 40

    8,084.40
    +44.04 (+0.55%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week

George Budwell, The Motley Fool
·2-min read
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week

After a blistering start to the year, small-cap biotech stocks made a U-turn in the second week of February. Speaking to this point, shares of the optical genome mapping company Bionano Genomics (NASDAQ: BNGO), the next-generation DNA sequencing company Pacific Biosciences of California (NASDAQ: PACB), and the genomics medicine company Sangamo Therapeutics (NASDAQ: SGMO) all tumbled by double digits through the first four days of trading this week, according to data provided by S&P Global Market Intelligence. Prior to this downturn, Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics were all up by double digits for the year.

Continue reading